Invus Public Equities, L.P. has bought stock on 15 days since Nov 2017
10% owner at Scholar Rock Holding Corporation, and 5 other companies
SEC CIK 0001340097 · Filings on SEC.gov ↗
Invus Public Equities, L.P.'s record
3 months after each buy, from the first price a copier could get.
5 buys since 2017 with 3 months of prices.
Companies
Every filing
21 filings since Nov 2017, newest first
Scholar Rock Holding Corp
10% owner
Glycomimetics Inc
10% owner
Glycomimetics Inc
10% owner
Glycomimetics Inc
10% owner
Glycomimetics Inc
10% owner
Scholar Rock Holding Corp
10% owner
Glycomimetics Inc
10% owner
Glycomimetics Inc
10% owner
Glycomimetics Inc
10% owner
Scholar Rock Holding Corp
10% owner
Omega Therapeutics, Inc.
10% owner
Seer, Inc.
10% owner
Lexicon Pharmaceuticals, Inc.
Director and 10% owner
Seer, Inc.
10% owner
Sqz Biotechnologies Co
10% owner
Lexicon Pharmaceuticals, Inc.
Director and 10% owner
Lexicon Pharmaceuticals, Inc.
Director and 10% owner
Lexicon Pharmaceuticals, Inc.
Director and 10% owner
Lexicon Pharmaceuticals, Inc.
Director and 10% owner
Lexicon Pharmaceuticals, Inc.
Director and 10% owner
Lexicon Pharmaceuticals, Inc.
Director and 10% owner
About Invus Public Equities, L.P.
Invus Public Equities, L.P. is a Bermuda limited partnership investment firm that provides asset management services, including private equity investments, financial advisory, and investment management for public and private companies.( It forms part of the broader Invus platform, which has been investing alongside entrepreneurs since the mid-1980s and oversees multi‑billion‑dollar assets through affiliated entities such as Invus Group and Invus, L.P.( Invus Public Equities, L.P. is based at 750 Lexington Avenue in New York and operates as an institutional investor and corporate insider in U.S. public markets, including holding more than 10% of Scholar Rock Holding Corp (SRRK).(
The partnership is controlled by Invus Public Equities Advisors, LLC, its general partner, with Invus Global Management, LLC acting as the managing member of that advisor, aligning the public-equities strategy with the wider Invus investment platform.( As of December 31, 2024, Invus Public Equities, L.P. directly held over 9.25 million shares of Scholar Rock common stock and additional warrants to purchase up to 1.575 million shares, reflecting its role as a significant long-term shareholder in the life sciences sector.( Through its affiliated advisory entities and family office relationships, Invus Public Equities, L.P. participates in strategic investments across industries, leveraging Invus’s continuous capital base and entrepreneurial partnership model.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.